BIOVIE INC.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
BioVie Inc. is a clinical-stage pharmaceutical company developing drug therapies for neurological and liver diseases, including treatments for Alzheimer's disease, Parkinson's disease, and cirrhosis of the liver.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Palumbo Joseph MChief Medical Officer | Buy | $10K | 4,843at $2.16 | Aug 28, 2026 |
| KIM JOANNE WENDYChief Financial Officer | Buy | $5K | 2,500at $2.18 | Aug 28, 2026 |
| Chappell Amy SuzonDirector | Buy | $2K | 727at $2.16 | Aug 28, 2026 |
| DO CUONG VPresident & CEO | Buy | $32K | 15,210at $2.08 | Aug 27, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable BIVI activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.